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Abstract  
BACKGROUND: Neuraxial clonidine is utilized for peri-operative analgesia in children of all ages. 
Preclinical studies in the postnatal rat allow comparison of the relative toxicity and safety of spinal 
analgesics throughout postnatal development.  
METHODS: Rat pups aged 3, 7 or 21 postnatal (P) days were briefly anesthetized for intrathecal 
injections of saline or clonidine. At each age, the maximum tolerated, anti-nociceptive (increased 
hindlimb mechanical withdrawal threshold) and anti-hyperalgesic (hindpaw carrageenan 
inflammation) doses were determined. Lumbar spinal cord sections were assessed for apoptosis 
and cell death (histology, activated caspase-3 immunohistochemistry, Fluoro-Jade C staining), 
histopathology (haematoxylin and eosin staining), and increased glial reactivity (microglial and 
astrocytic markers). P3 intrathecal ketamine sections served as positive controls. In additional 
groups, thermal latency and mechanical withdrawal threshold were measured at P35.   
RESULTS: Intrathecal clonidine produces age- and dose-dependent analgesia in rat pups. 
Maximal doses of clonidine did not alter the degree or distribution of apoptosis or increase glial 
reactivity in the neonatal spinal cord. No spinal histopathology was seen 1 or 7 days following 
injection at any age. Intrathecal clonidine did not produce persistent changes in reflex sensitivity 
to mechanical or thermal stimuli at P35.  
CONCLUSIONS: Intrathecal clonidine in the postnatal rat did not produce signs of spinal cord 
toxicity, even at doses much greater than required for analgesia. The therapeutic ratio (maximum 
tolerated dose/anti-hyperalgesic dose) was >300 at P3, >30 at P7, and >10 at P21. These data 
provide additional information to inform the clinical choice of spinal analgesic agent in early life.  
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Introduction 
Preclinical work demonstrated that spinal delivery of clonidine produced potent analgesia (1,2) 
through an effect upon spinal alpha2-adrenergic receptors (3). Subsequent human studies with 
neuraxial clonidine demonstrated clinical efficacy in adults (4) for the management of acute post-
operative (5,6), labor (7,8) and post-cesarean (9) pain; as well as for longer-term management of 
chronic neuropathic (10,11) and cancer pain (12).  In pediatric practice, spinal clonidine has been 
used primarily for peri-operative pain management; either as an additive to prolong analgesia with 
single-shot caudal local anesthetic (13-15) or to improve analgesia and reduce local anaesthetic 
requirements in epidural infusions (16,17). Although the majority of controlled trials have been 
conducted in infants and children, neuraxial clonidine has also been used in neonates, via either  
the caudal (18-20) or intrathecal route (21,22).  
 Laboratory studies have confirmed that spinal alpha2 agonist analgesic mechanisms are 
functional from early development, and intrathecal clonidine (23) and epidural dexmedetomidine 
(24,25) have both anti-hyperalgesic and anti-nociceptive effects in rat pups from the third 
postnatal (P3) day. Epidural dexmedetomidine produces spinally-mediated dose-dependent 
analgesic effects at all postnatal ages, but the sensitivity to sedative (24) and cardiovascular (25) 
side-effects is also increased in early life.  
 The benefits of spinal analgesia must always be balanced by the potential risk of 
neurotoxicity when drugs are administered in relatively high concentrations close to the spinal 
cord, and adequate preclinical testing before routine clinical use has been advocated (26-28). In 
adult animals, repeated injections or continuous infusions of spinally administered clonidine for 14 
days or longer, have not produced neurotoxic effects in rats (29,30) or dogs (31,32), and bolus 
doses did not reduce spinal cord blood flow in sheep (33) or pigs (34).  
Responses to analgesics and anesthetics may differ in the developing nervous system 
(35). In particular, anesthetics with γ−amino butyric acid (GABA) agonist or n-methyl-D-aspartate 
(NMDA) antagonist action increase neuronal apoptosis or cell death in the primate (36-39) and 
rodent brain (40-42). Accordingly, it is important when evaluating novel neuraxial therapeutics for 
neonates and infants, to define the potential effects of the agent with respect to the developing 
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spinal cord. We have recently developed a model for assessing spinal toxicity in the neonatal rat 
that includes evaluation of: i) dose-dependent analgesic effects; ii) histopathology, neuronal 
apoptosis and glial reactivity in the spinal cord at doses up to the maximum tolerated; and iii) 
functional outcomes (43,44). Calculation of a therapeutic ratio (toxic dose/analgesic dose) allows 
comparison of the effects of different drugs at different postnatal ages. In this model, morphine 
had a high therapeutic ratio, i.e. toxicity was not seen at 300 times the analgesic dose in neonatal 
rats (44). In contrast, intrathecal ketamine increased apoptosis and glial reactivity in the spinal 
cord and produced persistent changes in gait and mechanical threshold in the same dose range 
as analgesia, i.e. its therapeutic ratio was <1 (43). As clonidine is a potential alternative to 
ketamine for caudal analgesia in pediatric patients (15), we have now evaluated the analgesic 
effects and potential for spinal apoptosis and toxicity following single-dose intrathecal clonidine in 
the postnatal rat. 
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Methods  
Experimental animals 
The study protocol and experiments were performed with personal and project licenses approved 
by the UK Home Office, in a laboratory approved for regulated procedures, and in accordance 
with the requirements for the care of laboratory animals of the United Kingdom Animal (Scientific 
Procedures) Act 1986. Sprague-Dawley dams and litters were bred in-house in the Biological 
Services Unit University College London, and were maintained on a 12-h light/dark cycle at 
constant ambient temperature with free access to food and water. Postnatal (P) day 3, 7 or 21 
male and female rat pups, with mean body weights of 10, 16 and 54 grams respectively, were 
assigned to treatment groups. Within each litter, pups were randomly selected, numbered, and 
assigned to treatment groups. Data from animals within the same litter were treated as 
independent values, and treatment groups and group comparisons comprised animals from more 
than one litter. Overall, 12 litters from each age group were utilized. An independent colleague 
coded drug solutions to ensure the experimenter was unaware of treatment allocation during 
testing. The degree of handling and duration of maternal separation was minimized, and was the 
same for saline control and clonidine treatment animals. Litters were restricted to a maximum of 
12, and pups were weaned into same sex cages at P21.  
Behavioral testing 
In P3, P7 and P21 rats, mechanical withdrawal thresholds were measured with hand-held 
von Frey hairs (vFh) that apply a logarithmically increasing force (vFh 5 = 0.13g to vFh 13 = 
7.8g)(45). Testing was performed on the dorsal hindpaw as it is difficult to maintain body 
temperature or reliably apply mechanical stimuli to the plantar surface through an elevated mesh 
platform in small pups. Rats were lightly restrained on a flat bench surface and von Frey hairs 
were applied 5 times at one-second intervals to the dorsal surface of the hindpaw, as previously 
described (24,43,45,46). The number of evoked flexion reflexes to increasing intensity stimuli was 
recorded, until a given stimulus evoked five withdrawal responses or a supra-threshold cut-off 
pressure was reached (7.8g at P3, 13 g at P7, or 60g at P21).  
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 To evaluate any persistent changes in sensory function following intrathecal injection at 
P3, P7 or P21, sensory thresholds were measured at 5 weeks of age (P35). Following habituation 
on an elevated mesh platform, the mechanical stimulus (electronic von Frey device; Dynamic 
Plantar Aesthesiometer, Ugo Basile) was applied to the mid-plantar surface of the hindpaw. The 
mechanical threshold was averaged from 3 measures of the force (0 to 50 grams; ramp 20 
grams/sec) required to produce hind-limb withdrawal. Thermal withdrawal latency was 
determined using a modified Hargreaves Box (University Anesthesia Research and Development 
Group, University of California San Diego, La Jolla, California)(47), consisting of a glass surface 
(maintained at 30 °C) on which the rats were placed in individual Plexiglas cubicles. The thermal 
nociceptive stimulus from a focused projection bulb positioned below the glass surface was 
directed to the mid-plantar hindpaw. Latency was defined as the time required for the paw to 
show a brisk withdrawal as detected by photodiode motion sensors that stopped the timer and 
terminated the stimulus. In the absence of a response within 20 seconds, the stimulus was 
terminated (cut-off time). Thermal latency was the average of three measures from each hindpaw. 
Intrathecal injection technique  
 Pups were anesthetized with halothane (3-5%) in oxygen and air. Percutaneous 
intrathecal injections were made at the low lumbar level (intervertebral space L4-5 or L5-L6) with 
a 30-gauge needle perpendicular to the skin, connected to a micro-injector and 50 µl Hamilton 
syringe. Based on our previous work (44), an injectate volume of 0.5 µl per gram bodyweight was 
used as this provides a uniform spread across lumbar and low thoracic segments in rat pups of all 
current age (and corresponding weight) groups. Following preparation of different concentrations 
of clonidine, an independent colleague coded samples of drug and saline, to ensure the 
experimenter (SMW) was unaware of treatment group during behavioral testing.    
Intrathecal clonidine dose  
Determination of maximum tolerated dose.  
In pilot experiments, intrathecal clonidine hydrochloride (Sigma-Aldrich, St Louis, MO) dissolved 
in sterile saline were administered to P3, P7 and P21 pups in escalating doses of 0.1, 0.3, 1, 3, 
10, and 30mg/kg. Dose escalation was limited by behavioral disturbance and weight loss, rather 
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than by acute cardiovascular collapse or sedation and respiratory depression. Doses resulting in 
marked behavioral disturbance (reduced activity and freezing, alternating with agitation or 
excitation) were also associated with failure of normal daily weight gain or actual weight loss. 
Behavioral and motor changes were more apparent in the older pups, and occurred at lower 
doses. Following doses of 3mg/kg clonidine and above in P21 pups, piloerection, urinary voiding 
and shivering with significant hypothermia (temperature <31C) were also observed. As a result, 
temperature was monitored at intervals in all pups by holding a surface electrode between the 
upper limb and thorax in the ‘axilla’ of P3 pups or inserting a rectal probe in P10 or P21 pups. A 
warming protocol (thermostatically controlled heating blanket within open topped Perspex 
container) was established to ensure that body temperature was maintained after injection of 
saline or clonidine in subsequent experimental groups. The maximum tolerated dose of 
intrathecal clonidine was defined as the dose that did not produce weight loss in individual 
animals (when comparing values pre- and 24 hrs post-injection of clonidine) or significant group 
differences from saline controls. This provided a quantifiable outcome that could be standardized 
across the postnatal ages. In subsequent experimental groups, the maximum tolerated dose at 
each age produced mild acute behavioral changes, but body temperature and body weight were 
maintained. 
 For clarity, intrathecal doses are expressed in terms of mg/kg. However, as the 
concentration of drug is important for the direct effect upon local tissues after intrathecal delivery, 
the range of concentrations and mean total dose for each treatment group are also presented in 
Table 1. 
Evaluation of anti-nociceptive doses.  
Intrathecal clonidine doses up to the maximum tolerated were administered to evaluate acute 
anti-nociceptive effects. Individual pups received single doses of saline or clonidine. Mechanical 
withdrawal threshold was determined at baseline, correct intrathecal placement was confirmed by 
a significant increase in threshold 30 minutes after injection, and thresholds were again measured 
prior to sacrifice and spinal cord harvesting at 24 hours or 7 days post injection. Single injections 
of the maximum tolerated dose were administered for tissue analysis (44), as our model aims to 
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deliver the highest possible concentration of drug to evaluate local tissue toxicity, and repeated 
administration is not feasible as intrathecal catheters can produce confounding injuries in small 
pups (23). To confirm that effects at these doses were not solely due to systemic absorption, 
mechanical thresholds 30 minutes following subcutaneous administration of clonidine in the 
midlumbar region (10mg/kg at P3 or 3mg/kg at P7 and P21 in 5 µl/g; n=6 per group) were also 
evaluated.   
 In separate groups of animals, the maximum tolerated dose of intrathecal clonidine was 
administered to P3 (10mg/kg), P7 (3mg/kg) or P21 (1mg/kg) pups (n=8 per group). Control 
animals received intrathecal saline (n=6-8 per group). Mechanical withdrawal thresholds were 
measured at baseline and 30 minutes after injection to confirm intrathecal placement. Animals 
were maintained and regularly reviewed in the UCL Biological Services Unit, weaned into same-
sex cages at P21, and weight, mechanical withdrawal threshold and thermal withdrawal latency 
were measured at 5 weeks of age.  
Evaluation of anti-hyperalgesic doses.  
Hindpaw inflammation was induced in P3, P7 and P21 pups by injection of 1 µl/g of 2% lambda 
carrageenan (Sigma-Aldrich) into the mid-plantar surface of the left hindpaw under brief 
halothane (2-4%) in oxygen anesthesia (24). Mechanical withdrawal thresholds were measured at 
baseline and 3 hours following carrageenan to quantify the degree of hyperalgesia. Intrathecal 
saline or clonidine (0.03 – 0.3 mg/kg; n=5-6 all groups) was administered as described above. 
Mechanical withdrawal thresholds were measured 15 and 30 minutes following injection, with the 
investigator (SMW) unaware of the treatment allocation.   
Spinal cord preparation, staining and analysis 
 Spinal cord tissue was analyzed 24 hours and 7 days after injection as previously 
described (43,44) (n=4 per treatment group). In brief, animals were terminally anesthetized with 
100mg/kg intraperitoneal pentobarbitone, and then transcardially perfused with heparinised saline 
followed by 4% paraformaldehyde. Spinal cords were dissected, postfixed in 4% 
paraformaldehyde, and then cryoprotected in 30% sucrose. Using a cryostat, 7 and 14 micron 
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sections of lower lumbar spinal cord were taken and mounted on Fischer Superfrost Plus (Fischer 
Scientific, Houston, TX) slides and stored at -700C.  
 For each analysis, sections were coded and the investigator was unaware of the 
treatment group. For quantitative analyses, at least 4 non-consecutive sections of lumbosacral 
cord from each animal were examined and the mean determined. Different sections were utilized 
for caspase-3 immunohistochemistry, Fluoro-Jade C staining or haematoxylin and eosin (H&E) 
staining at 24 hours, and for H&E staining and glial immunoreactivity at 7 days. Sections from P3 
pups that had received 10mg/kg intrathecal preservative-free ketamine hydrochloride (Sigma-
Aldrich, St Louis, MO) as previously described (43), were stained in parallel to act as a positive 
control for the staining protocol and to ensure the sample size was sufficient to detect treatment 
effects previously associated with both structural and functional changes (43).  All statistical 
analysis was calculated with n representing the number of animals within each treatment group.  
Fluoro-Jade C staining.  
Fluoro-Jade C (FJ-C; Millipore, Temecula, CA) staining was performed as previously described 
(48) on 14 micron spinal cord sections prepared from tissue collected 24 hours following 
intrathecal injection. In addition to 0.0001% FJ-C, slides were incubated with the DNA stain 4',6-
diamidino-2-phenylindole (DAPI 0.0001%; MP Biomedicals, Solon, OH) to aid visualization and 
confirm tissue integrity of the sections. Slides were examined with the appropriate wavelength 
fluorescent microscopy, and the number of immunofluorescent cells and their distribution in the 
dorsal horn, ventral horn or adjacent to the central canal were recorded.  
Activated caspase-3 immunohistochemistry.  
To further assess apoptosis, additional spinal cord sections obtained from P3 and P7 animals 24 
hours following intrathecal injection were incubated with monoclonal activated caspase-3 
antibody (1:100 Cell Signaling, Beverly, MA) for 72 hours at 4C. Biotinylated goat anti-rabbit 
secondary antibody (Vector, Burlingame, CA) was applied at 1:250 for 45 min at room 
temperature, followed by avidin-biotin-peroxidase complex (ABC reagent; Vector, Burlingame, 
CA) for 30 min. Staining was developed with DAB (Vector, Burlingame, CA) for 12 min. Sections 
were lightly counterstained with haematoxylin, dehydrated and coverslipped (Permount, Fischer 
SP15, Fair Lawn, NJ). Slides were coded and the number and location (dorsal horn, ventral horn 
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or adjacent to central canal) of caspase-3 immunoreactive cells were counted under high power 
light microscopy.  
Histology.  
A neuropathologist (MG) evaluated seven-micron spinal cord sections from all experimental 
groups, sacrificed at 1 or 7 days post-injection. Haematoxylin and eosin stained sections were 
examined for histopathological changes (including tissue necrosis, gliosis, and inflammation) and 
apoptotic cell numbers were counted under high power. 
Glial fibrillary acidic protein (GFAP) and ionized calcium binding adapter molecule 1 (Iba1) 
immunohistochemistry.  
Tissue obtained 7 days following intrathecal injection was incubated with primary antibodies 
against astrocyte (1:1500 mouse anti-GFAP; Chemicon, Temecula, CA) and microglial (1:1000 
rabbit anti-Iba-1; WAKO, Richmond, VA) markers for 48 hours at 4C. Flourescent secondary 
antibodies 1:250 Alexa 488 goat anti-mouse and 1:250 Alexa 594 goat anti-rabbit (Molecular 
Probes, Eugene, OR) were applied for 1 hour at room temperature. Slides were coverslipped with 
ProLong antifade reagent with DAPI (Molecular Probes, Eugene, OR). Spinal cord sections were 
imaged using standardized settings on a microscope (Olympus BX51 microscope with 
appropriate wavelength fluorescence illuminator; Olympus America Inc, Center Valley, PA) 
equipped with a digital camera and image-capture software. The mean intensity of 
immunofluorescence within a fixed area region of interest in the dorsal horn was quantified for 
each section (Image Pro Plus software, Media Cybernatics Inc, Silver Spring, MD).    
Statistical Analysis 
For evaluation of mechanical withdrawal threshold in pups, the number of withdrawal responses 
was plotted against the mechanical stimulus (force expressed as grams on log10 scale). A 
sigmoidal stimulus-response curve with non-variable slope was constructed using non-linear 
regression curve fit. The mid point of the curve (50% effective force; EF50) was determined and 
designated the threshold (24,46). In adults, mechanical withdrawal thresholds and thermal 
latencies were the mean of 3 values for each hindpaw. The degree of reversal of inflammatory 
hyperalgesia for each animal was calculated from the mechanical withdrawal thresholds at 
different time points: [(30 minutes post-clonidine - inflamed) / (baseline – inflamed) x 100]. 
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Treatment groups were compared with one way analysis of variance (ANOVA) followed by 
Bonferroni’s post-hoc test for multiple comparisons or Dunnett’s multiple comparison, or Student's 
t-test if comparison was limited to 2 groups. P35 sensory threshold values were tested for 
normality (D’Agostino and Pearson normality test) and also assessed by two-way ANOVA with 
treatment (saline or different clonidine doses) and sex (male or female) as variables. Data was 
analyzed using Prism Version 5.0 (GraphPad, San Diego, CA). P<0.05 was considered 
statistically significant. 
Results  
Intrathecal clonidine produces dose-dependent analgesic effects at all postnatal 
ages 
Effects of clonidine on mechanical withdrawal threshold.  
The maximum tolerated intrathecal clonidine dose was 10mg/kg at P3 and 3mg/kg at P7. These 
doses produced mild behavioral effects initially, that did not preclude sensory testing at 30 
minutes, and body weight was maintained at 24 hours and 7 days. In P21 pups, 3mg/kg clonidine 
produced more marked behavioral effects (reduced movement but initial excitatory responses on 
handling), but minimal weight loss at 24 hours (56.7±1.1g at baseline vs 54.7±1.8g), and this 
dose was used for acute evaluations. However, as body weight was lower than saline controls by 
3 days post-injection, the lower dose of 1mg/kg was designated the maximum tolerated dose in 
P21 pups for evaluation at 7 days post injection and at P35. 
 Mechanical withdrawal thresholds increase with postnatal age, from a mean of 1.3g at 
P3, 1.6g at P7 to 11.9g at P21 (Table 2). Intrathecal clonidine produces dose-dependent anti-
nociceptive effects at all postnatal ages. Thirty minutes following intrathecal injection, mechanical 
withdrawal thresholds did not differ from baseline in the saline control groups, but were 
significantly increased by 1mg/kg clonidine at all postnatal ages (P<0.05 or P<0.01; one way 
ANOVA with Dunnett’s comparison to baseline; Fig. 1). Systemic administration of the highest 
clonidine dose also increased mechanical withdrawal threshold compared with baseline, but 
effects were significantly less than when the same dose was administered intrathecally at P3 
(10mg/kg s.c. vs IT = 1.3±0.08g vs 3.0±0.14g; P<0.01), at P7 (3mg/kg s.c. vs IT = 2.8±0.19g vs 
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3.8 ± 0.25g; P<0.05), or at P21 (3mg/kg s.c. vs IT = 30±3g vs 74±6g; P<0.01 one way ANOVA 
with Bonferroni post hoc comparisons). 
Inflammatory hyperalgesia.  
Three hours following hindpaw injection of carrageenan, mechanical withdrawal thresholds in the 
inflamed paw were significantly decreased at all postnatal ages (Fig. 2A; P<0.001 paired two-way 
Student’s t-test). The minimum dose of intrathecal clonidine that produced a significant reversal of 
inflammatory hyperalgesia was 0.03mg/kg at P3 and 0.1mg/kg at P7 (P<0.01), and 0.3mg/kg at 
P21 (P<0.05, one way ANOVA with Dunnett’s comparison to saline; Fig. 2B). Consistent with 
previous data following epidural dexmedetomidine (24), anti-hyperalgesic effects of intrathecal 
clonidine were seen at lower doses than anti-nociceptive effects at all ages. In addition, age-
dependent analgesic effects were evident following inflammation, with lower dose requirements in 
the younger pups. 
Intrathecal clonidine does not produce persistent changes in sensory thresholds 
Following intrathecal injection of clonidine 10mg/kg at P3, 3mg/kg at P7 or 1mg/kg at P21, 
mechanical withdrawal thresholds (Table 2) and body weight (Table 3) did not differ from saline 
control groups 24 hours or 7 days following injection. In additional animals, more persistent 
effects on spinal reflex sensitivity were assessed at P35. There were no significant differences in 
mechanical withdrawal threshold or thermal withdrawal latency following intrathecal injection of 
clonidine or saline at P3, P7 or P21 (Table 2; n.s. one way ANOVA with Bonferroni multiple post-
hoc comparisons). There was no main effect of treatment (F3,36 = 0.43, P=0.73) or sex (F1,36 = 
0.71, P=0.55) on mechanical withdrawal threshold at P35. Similarly, there was no main effect of 
treatment (F3,36 = 0.23, P=0.87) or sex (F1,36 = 0.43, P=0.43) on thermal withdrawal latency at 
P35. Treatment accounted for 5.3% and 4%, and sex for <0.1% and 1.6% of total variance in 
mechanical threshold and thermal latency respectively (two-way ANOVA with treatment and 
gender as variables).  
Maximal tolerated doses of intrathecal clonidine do not increase apoptosis or 
produce histopathological changes in rat pups 
The number of Fluoro-Jade C positive neurons 24 hours following saline injection decreased with 
age (P4: 11.1±1.02; P8: 6.5±1.2; P22: 2.5±0.5; P<0.01 one way ANOVA linear trend) and the 
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majority were found in the dorsal horn (Fig. 3A,B). Intrathecal clonidine had no effect on the 
number or distribution of Fluoro-Jade C positive cells at any age. By contrast, intrathecal 
ketamine 10mg/kg at P3 significantly increased the number of Fluoro-Jade C positive cells in the 
lumbar spinal cord, with the greatest increase in the dorsal horn (Fig. 3A).  
 Similarly, maximum tolerated doses of intrathecal clonidine at P3 or P7 did not increase 
apoptotic cell counts as identified by activated caspase-3 immunohistochemistry (Fig. 4). 
Significant increases were seen in the P3 ketamine 10mg/kg positive control group.    
 Spinal cord sections stained with haematoxylin and eosin were evaluated for 
histopathological changes after intrathecal injection. The age related decrease in apoptosis is 
again demonstrated in data from animals 24 hours post injection (P4, P8, P22) and 7 days post 
injection (P10, P14, P28).  Within each age group, the number of apoptotic profiles following any 
dose of intrathecal clonidine did not differ from the saline control group (Fig. 5). None of the spinal 
cords showed histopathological changes such as necrosis, inflammation, or microglial nodules.  
Intrathecal clonidine does not increase glial reactivity in the neonatal spinal cord 
 Glial reactivity 7 days following intrathecal injection was assessed by 
immunohistochemistry for microglial (Iba1; Fig 6A,B) and astrocytic (GFAP; Fig.6C) markers. The 
mean density of Iba-1 or GFAP immunofluorescence in the dorsal horn was not altered by 
maximum doses of intrathecal clonidine at P3, P7 or P21. However, significant increases were 
seen in the P3 ketamine group (Fig. 6).    
Postnatal age and therapeutic ratio of intrathecal clonidine 
Based on the above results, the therapeutic ratio calculated as the quotient of the maximum 
tolerated dose and the minimum dose that significantly increased mechanical threshold in the 
uninjured paw was calculated as >10 at P3 (10/1) and >3 at P7 and P21 (3/1). Using the anti-
hyperalgesic dose as the measure of analgesic activity, the therapeutic ratio at P3 was  >300 
(10/0.03), at P7 was >30 (3/0.1), and at P21 was >10 for acute apoptosis (3/0.3) and >3 for 
persistent sensory effects (1/0.3). As the maximum dose was limited by systemic side-effects and 
there were no signs of local spinal toxicity, the ratio for spinal effects is designated as greater 
than the given ratio rather than an absolute value. 
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Discussion  
These are the first systematic studies evaluating the potential spinal toxicity of intrathecal 
clonidine in a neonatal model. Intrathecal clonidine dose-dependently reverses inflammatory 
hyperalgesia at all postnatal ages, and higher doses increase sensory thresholds in uninjured 
paws (i.e. have anti-nociceptive effects). Single maximum tolerated doses/concentrations of 
intrathecal clonidine did not produce signs of local tissue toxicity at any postnatal age as 
measured by several criteria. Firstly, intrathecal clonidine did not increase apoptotic cell counts 
identified by activated caspase-3 immunohistochemistry or histological examination, or alter the 
number or distribution of Fluoro-Jade C positive neurons 24 hours following injection. Intrathecal 
clonidine did not produce histopathological changes in the spinal cord or alter markers of 
microglial or astrocytic reactivity. Finally, intrathecal clonidine had no persistent effects on spinal 
cord reflex sensitivity to mechanical or thermal stimuli at P35. The absence of effects of clonidine 
were similar to those following morphine (44), but in contrast to the effects following intrathecal 
ketamine in P3 animals as reported previously (43) and confirmed in parallel sections in the 
current study. 
 Clonidine is an alpha-adrenergic agonist with an approximate 160-fold selectivity for the 
alpha2 vs alpha1 receptor (49). Early preclinical work pointed to the potent spinal action of alpha2 
agonists such as clonidine in regulating the processing of nociceptive information following both 
tissue and nerve injury in adult animals (1,2,50). Spinal alpha2 agonists have age- and dose-
dependent analgesic effects throughout postnatal development (23-25). The current study 
confirms reversal of hyperalgesia by intrathecal clonidine, with lower dose requirements in the 
youngest pups. Higher intrathecal doses are anti-nociceptive, and although maximum tolerated 
intrathecal doses produce additional systemic side-effects, analgesic effects are still more marked 
than when the same dose is administered systemically. 
Safety evaluation of spinal clonidine has been undertaken in adult dogs after repeated 
bolus (32) or extended continuous epidural (31) and intrathecal (51) delivery. No evidence of 
spinal pathology was observed. Similarly, intrathecal administration for 14 days did not result in 
toxicity in the adult rat (29,30). These findings are based on histological evaluation performed by 
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a neuropathologist, and similar methodology here has also failed to demonstrate histopathology 
in the cord of neonatal and young rats following single dose intrathecal clonidine. Of particular 
interest, clonidine has been reported to a have anti-inflammatory actions (52-55), and co-
administration reduces the local inflammatory effects evoked by chronic low dose intrathecal 
morphine in the canine model (51). Alpha2 agonists may also have specific advantages in 
combination therapy in early development. Systemic dexmedetomidine reduced general 
anesthetic-related apoptosis in P7 rats, although efficacy varied in different brain regions (56,57), 
and effects in the spinal cord have not been evaluated. The effect of combinations of different 
intrathecal analgesics and local anesthetics throughout postnatal development warrant future 
evaluation. 
Given the concern regarding general anesthesia in neonates and increased interest in 
neuraxial anesthesia (58), we have emphasized the need to develop a safety database to define 
the potential toxicity of agents for spinal delivery at different developmental ages (59). The 
present work with clonidine, and previous work with morphine (44), ketamine (43), and 
bupivacaine (60) represent the only systematic preclinical spinal safety data in postnatal rats. 
Several points should be emphasized. Assessment of developmental safety must take 
cognizance of the fact that there are age-dependent changes in connectivity in the developing 
spinal cord (35,61), and treatments that alter afferent traffic, such as NMDA antagonists (43) and 
general anesthetics (60,62) can increase apoptosis in the spinal cord, and persistently modify 
spinal cord structure and function (43,63,64). Accordingly, as in our previous studies (43,44), we 
specifically examined treatment effects at P3, P7 and P21; a developmental time span that 
extends from the critical neonatal period through to childhood in humans. Consistent with our 
current and previous reports, spontaneous apoptosis in the spinal cord of postnatal rats occurs 
largely in the dorsal horn from P2-P5, decreasing by P8-10 (65,66). The brief anesthesia used for 
our intrathecal injection protocol has no additional impact, as the number of apoptotic cells did not 
differ between naïve and intrathecal saline animals (44). Here, maximum tolerated doses of 
clonidine did not alter the number or distribution of apoptotic cell profiles as assessed by 
histological examination, activated-caspase 3 immunohistochemistry or Fluoro-Jade C staining. In 
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addition, there was no evidence of a delayed injury response as there was no histopathological 
change or increase in glial reactivity 7 days following injection. Following general anesthetic 
exposures that increase cortical and hippocampal apotosis in rodents, changes in higher 
cognitive functions such as learning and memory have been reported at intervals from 4 weeks to 
8 months (67). We evaluated sensory thresholds at P35, when both sensory (61) and motor 
(68,69) components of reflex function are fully mature, and descending modulation from the 
rostroventral medulla has reached adult patterns by P25 (70). Whereas intrathecal ketamine at 
P3 increased apoptosis and altered mechanical withdrawal thresholds and gait (43), single 
maximal doses of intrathecal clonidine did not alter reflex sensitivity at P35. 
Clonidine has an established role as a spinal adjuvant analgesic in pediatric practice, and 
clonidine via the intrathecal (71) or caudal/epidural (72) route has a greater effect than the same 
dose intravenously. Epidural clonidine 0.08-0.12 µg/kg/hr produces dose-dependent analgesia 
when added to local anesthetic infusions (17), and higher doses of clonidine alone (0.2µg/kg/hr 
preceded by bolus of 2µg/kg) provide analgesia at rest following abdominal surgery (73). 
Clonidine 1-2µg/kg prolongs analgesia when added to caudal local anesthetic, with 
cardiovascular and sedative side-effects at doses of 5µg/kg in children (15), but sensitivity to 
side-effects (apnoea, oxygen desaturation, and bradycardia) is greater  in neonates	   (18-20). 
Similarly, when added to intrathecal local anesthetic, clonidine prolonged analgesia in neonates 
(21), but an increased proportion were sedated and developed self-limiting apnea postoperatively 
(22). Caudal dexmedetomidine has analgesic properties (74) similar to clonidine (75) in infants 
and children, but there has been limited preclinical evaluation of toxicity (59,76).  
The merits of different spinal analgesics have been discussed in several clinical reviews, 
but concerns about the relative safety of different drugs and preparations have also been 
expressed (15,77-79). Current practice differs across centers and countries as the availability of 
preparations varies and there is limited clinical data relating to comparative efficacy or long-term 
outcomes (16,80). Within study comparisons of caudal clonidine and ketamine have variably 
reported more prolonged analgesia with ketamine (81,82) or no difference (83). Addition of 
clonidine to ketamine further prolonged analgesia in one study (84), but provided no benefit in 
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another (85). Between 2002 and 2009, the proportion of pediatric anesthetists adding clonidine to 
caudal local anesthetic in the UK increased, and use of caudal ketamine remained relatively 
stable (13,14). However, decreased use of ketamine in Europe (86) has been attributed to 
guidelines reporting laboratory toxicity with preservative-free ketamine in adult animals (87). Our 
previous study (43) and the direct comparisons utilized here, suggest that ketamine has specific 
developmental effects that reduce the safety margin for spinal administration in early 
development.  
One of the conundrums facing the interpretation of preclinical safety data is the 
translation of dosing from the animal model to the human condition. We have suggested that one 
useful strategy is to compare the therapeutic ratio (i.e. the minimum spinal dose at which toxicity 
is observed divided by the maximally therapeutic dose), as this would provide a conservative 
estimate for comparison of different agents. The definition of the therapeutic dose clearly 
depends upon the end point selected. In previous work, we evaluated anti-nociceptive effects of 
morphine to a mechanical stimulus (44). As ketamine has minimal effects on baseline thresholds, 
we evaluated anti-hyperalgesic effects following hindpaw inflammation (43). Here we evaluated 
both anti-nociceptive and anti-hyperalgesic effects of clonidine, and as shown previously in rat 
pups following epidural morphine (88,89) or epidural dexmedetomidine (24), lower doses of 
intrathecal clonidine were required to reverse inflammatory hyperalgesia than to produce anti-
nociceptive effects. Analgesic dose requirements for morphine, ketamine and clonidine were age-
dependent and lowest at P3. As analgesic requirements vary with the type of drug and with age 
(e.g. carrageenan-induced hyperalgesia was reversed by clonidine 30mcg/kg and ketamine 
3mg/kg at P3, and by clonidine 300mcg/kg and ketamine 15mg/kg at P21), equi-analgesic effects 
rather than absolute doses are used to calculate the relative therapeutic ratio. Using anti-
hyperalgesic doses, therapeutic ratios for intrathecal clonidine were >300 at P3, >30 at P7, and 
>10 at P21. Similarly, maximal doses of morphine did not produce toxicity, and the therapeutic 
ratio was high (44). By contrast, intrathecal ketamine increased apoptosis in the same dose range 
as analgesia, and the calculated therapeutic ratio did not exceed 1 (43). This approach has 
potential weaknesses. From the perspective of the spinal agent, the principal variable defining 
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local tissue effects are the local concentration of the drug in the spinal canal and the duration of 
that exposure (26). As repeated dosing via intrathecal catheters is not practical in small pups, 
single doses were given and the maximum testable dose of clonidine, morphine and ketamine 
was limited by systemic side effects. While systemic side effects are of concern, our principal 
focus for toxicity is the local effect upon spinal tissues. In the event that the maximum tolerable 
dose after intrathecal delivery is not associated with toxicity, we can only conclude that the 
therapeutic ratio is at least, or greater than, a certain value. This value will be low if systemic side-
effects preclude assessment of higher doses/concentrations. Conversely, if local spinal toxicity 
occurs at a dose lower than the therapeutic analgesic effect, one can assert that the therapeutic 
ratio is 1 or less. We would argue that despite these limitations on achieving absolute values, this 
methodology allows us to compare the relative safety margin of different drugs at given stages of 
development. A relatively wide safety margin has been demonstrated with morphine (44) and now 
with clonidine. The comparisons with ketamine presented here and previously (43), confirm that 
spinal clonidine has a wider safety margin than spinal ketamine in the neonatal rat. These data 
provide additional information to inform the clinical choice of spinal analgesic in early life. 
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Figure Legends 	  
Figure 1. Dose-dependent anti-nociceptive effects of intrathecal clonidine. Mechanical withdrawal 
thresholds at baseline and 30 minutes following intrathecal (I.T.) injection of saline or clonidine 
(CL) 1, 3 or 10mg/kg in postnatal day (P) 3, 7 or 21 rat pups are shown. Data points = 
mean±SEM, n=6-8 per treatment group, *P<0.05 ***P<0.001 one way ANOVA with Dunnett’s 
comparison to baseline. 
 
Figure 2. Anti-hyperalgesic effects of clonidine. A, Mechanical withdrawal thresholds are 
significantly reduced from baseline 3 hours following hindpaw carrageenan injection at postnatal 
day (P) 3, 7, and 21. Bars = mean±SEM, ***P<0.001 Student’s two-tailed paired t-test. B, The 
degree of reversal of carrageenan-induced hindpaw inflammatory hyperalgesia [30mins post 
dose – inflamed/baseline – inflamed) x100] is shown following intrathecal (I.T.) saline (0) or 
increasing doses of intrathecal clonidine at postnatal (P) day 3, 7 and 21. Data=mean±SEM, n=5-
7 per group, *P<0.05 **P<0.01 vs saline, one way ANOVA with Dunnett’s comparison to saline.  
 
Figure 3. Fluoro-Jade C positive cell counts 24 hours following intrathecal injection at postnatal 
day 3 (A), 7 or 21 (B). The number of cells in the whole section (total) and the proportion 
distributed within the dorsal horn (dorsal horn) are averaged from at least 4 non-consecutive 
sections per animal. I.T.=intrathecal; P=postnatal day; CL=clonidine 1, 3 or 10mg/kg; ket 10 = 
ketamine 10mg/kg. Bars = mean±SEM, n= 4 animals per group. **P<0.01 ket 10 vs all groups in 
total section; ##P<0.01 ket 10 vs all groups in dorsal horn; one way ANOVA with Bonferroni post-
hoc comparisons. 
 
Figure 4. A, Example of lumbar spinal cord section following intrathecal ketamine at P3 with 
activated-caspase 3 immunopositive cells stained brown and highlighted with arrows. B, 
Activated-caspase 3 immunopositive cell counts 24 hours following intrathecal injection at 
postnatal day 3 or 7. Numbers are averaged from at least 4 non-consecutive sections per animal. 
	   31	  
I.T=intrathecal; P=postnatal day; CL=clonidine 1, 3 or 10mg/kg; ket=ketamine 10mg/kg. Bars = 
mean±SEM, n= 4 animals per group. **P<0.01 ket 10 vs all other P3 groups; one way ANOVA 
with Bonferroni post-hoc comparisons. 
 
Figure 5. Apoptotic cell counts from haematoxylin and eosin stained sections. Numbers are 
averaged from at least 5 sections per animal 24 hours or 7 days following intrathecal injection on 
postnatal day 3, 7 and 21. Counts following intrathecal saline or any dose of intrathecal clonidine 
did not differ at any time point (n.s. one way ANOVA). 	  
Figure 6. A, Representative spinal cord sections demonstrating Iba1 immunofluorescent staining 
7 days following injection of i) intrathecal clonidine 10mg/kg or ii) intrathecal ketamine 10mg/kg. 
B, Quantification of Iba1 immunofluoresence in the dorsal horn 7 days following intrathecal (I.T.) 
saline, clondine 1, 3 or 10mg/kg (CL 1, 3, 10) or ketamine 10mg/kg (ket 10) at postnatal day (P)3, 
7 or 21. C, Quantification of GFAP immunofluoresence in the dorsal horn in the same 
experimental groups as above. Bars=mean±SEM, n=3-4 animals per group. *P<0.05 ketamine 
10mg/kg vs saline or clonidine 10mg/kg at P3; one way ANOVA with Bonferroni post-hoc 
comparisons.   
 





	   33	  
FIGURE 2 
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FIGURE 6 
 
 
 
 
 
 
 
